Background
==========

Riociguat, an oral soluble guanylate cyclase (sGC) stimulator, is currently being investigated for the treatment of pulmonary hypertension. Riociguat has a novel dual mode of action, directly stimulating sGC, independent of nitric oxide (NO), and increasing sensitivity of sGC to NO. Riociguat thereby restores the NO--sGC--cGMP pathway, which is impaired in pulmonary hypertension. Three pharmacokinetic studies were performed to characterize the absorption behavior of riociguat including absolute bioavailability, food effects, and dose-proportionality.

Methods
=======

The pharmacokinetic and safety profiles of riociguat were investigated in three open-label, randomized, crossover studies in healthy male subjects. In the absolute bioavailability study, fasted subjects (n=22) received a single oral immediate-release dose of riociguat 1 mg or intravenous riociguat 1 mg. In the food-effects study, subjects (n=23) received a single oral dose of immediate-release riociguat 2.5 mg after a 10-hour fast or after a high-fat high-calorie breakfast eaten within 30 minutes of dosing. In the dose-proportionality study, fasted subjects (n=24) received a single oral dose of riociguat 0.5, 1, 1.5, 2, or 2.5 mg.

Results
=======

In the absolute bioavailability study, riociguat exposure was similar after oral and intravenous dosing and oral bioavailability was 94% (95% confidence interval: 83--107) (Figure [1](#F1){ref-type="fig"}). Mean C~max~ of riociguat was slightly lower after oral dosing compared with intravenous dosing. In the food-effects study, a high-fat breakfast had little effect on the extent of riociguat absorption, although absorption was delayed (Table [1](#T1){ref-type="table"}). In fed subjects, the C~max~ of riociguat decreased by 35.3% and t~max~ increased compared with fasted subjects. In the dose-proportionality study, systemic exposure of riociguat was dose-proportional over 0.5--2.5 mg (Figure [2](#F2){ref-type="fig"}) with low intra-individual variability and moderate-to-high inter-individual variability. Riociguat was well tolerated in all studies. The most common treatment-emergent and riociguat-related adverse events were headache, flushing, and nasal congestion across all studies.

![Plasma riociguat concentrations following single 1 mg intravenous (n=22) or oral doses of riociguat (n=22) (absolute bioavailability study).](2050-6511-14-S1-P7-1){#F1}

###### 

Riociguat pharmacokinetics following a single oral dose of riociguat 2.5 mg in fed and fasted subjects (food-effects study)

  Parameter^a^        Fasted (n=23)          Fed (n=23)             Estimated fed:fasted ratio (%)   90% CI       %CV
  ------------------- ---------------------- ---------------------- -------------------------------- ------------ ------
  C~max~ (μg/L)       84.2 (44.7−152.7)      54.8 (28.9−91.4)       64.7                             57.8--72.5   22.5
  t~max~ (h)          1 (0.5−4.0)            4 (1.5−6.0)            ---                              ---          ---
  AUC~0-∞~ (μg⋅h/L)   572.2 (112.3−1300.0)   505.6 (113.3−1205.0)   88.3                             82.2--95.0   14.3

AUC, area under the plasma concentration--time curve; CI, confidence interval; C~max~, maximum riociguat plasma concentration; CV, coefficient of variation; t~max~, time to reach C~max~.

^a^Data are mean (range) except t~max~, which is median (range).

![Mean plasma riociguat concentrations following single oral doses of riociguat 0.5, 1.0, 1.5, 2.0, or 2.5 mg (n=24) (dose-proportionality study). LLOQ, lower limit of quantification.](2050-6511-14-S1-P7-2){#F2}

Conclusion
==========

Riociguat shows complete oral absorption with no clinically relevant food effects; riociguat can therefore be taken with or without food. Riociguat systemic exposure increased dose proportionally over all doses (0.5--2.5 mg), supporting the suitability of the individualized dose-titration scheme used in the Phase III pulmonary arterial hypertension (PATENT) and chronic thromboembolic pulmonary hypertension (CHEST) studies.
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